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New WHO guidance on prevention and treatment of 
maternal peripartum infections
WHO estimates that the global prevalence of maternal 
sepsis is 4·4% among livebirths, representing more than 
5·7 million cases per year.1 Important variations exists 
between regions, with higher incidence in low-income 
and middle-income countries (up to 7%) compared with 
high-income countries (1–2%).2 Despite the relative low 
prevalence and the availability of interventions for its 
prevention and treatment, maternal sepsis remains a 
life-threatening condition and one of the leading direct 
causes of maternal mortality worldwide, accounting for 
up to 10% of maternal deaths.3 Up-to-date guidance on 
eﬀ ective interventions to reduce the global burden of 
maternal infections at a time when they are most likely to 
aﬀ ect maternal and newborn survival is certainly needed.
This week, WHO launches new guidance on 
interventions for women to prevent and treat infections 
occurring during the peripartum period.4 In this 
guideline, the term “maternal peripartum infection” was 
adopted to consider bacterial infections of the genital 
tract or its surrounding tissues occurring at any time 
between the onset of rupture of membranes or labour 
and the 42nd day post partum. The overall approach of 
these recom mendations is to highlight and encourage 
eﬀ ective practices that are underused and discourage 
practices that are either ineﬀ ective or potentially 
harmful to women, their babies, and the general public. 
Caesarean section is the most important risk factor for 
maternal infection in the immediate postpartum period. 
The main strategies to prevent post-caesarean infections 
include the observation of fundamental surgical aseptic 
techniques and use of prophylactic antibiotics. However, 
the global use of prophylactic antibiotics for caesarean 
births varies largely between hospitals,5 in part because 
of lack of institutional protocols and uncertainties about 
the antibiotic regimen of choice and correct timing of 
administration. The WHO guideline panel made strong 
recommendations regarding the administration of 
prophylactic antibiotics before skin incision, rather than 
after umbilical cord clamping, for women undergoing 
elective or emergency caesarean section. In view of the 
overall evidence in favour of prophylactic antibiotics, 
the panel acknowledged that antibiotics are also 
eﬀ ective when given after umbilical cord clamping, 
particularly in cases of emergency caesarean section 
where the available time to administer antibiotics 
before surgery might be limited. Evidence suggests 
that a single dose of ﬁ rst-generation cephalosporin or 
penicillin should be used in preference to other classes 
of antibiotics, particularly because these are broad-
spectrum antibiotics and widely available in all settings.
The guideline recommends routine antibiotic 
prophylaxis for other obstetric conditions for which the 
risk of maternal infection is high, for instance in women 
presenting with a third-degree or fourth-degree perineal 
tear after vaginal birth. In making this recommendation, 
the panel placed emphasis on infection reduction 
of a potentially contaminated wound which can 
aggravate long-term consequences of third-degree 
or fourth-degree perineal tears (eg, ﬂ atus or faecal 
incontinence with considerable impact on quality of life). 
Likewise, routine antibiotic prophylaxis is recommended 
for manual removal of the placenta. Although evidence 
to support this practice is inconclusive, indirect evidence 
from studies on caesarean section and abortion, as 
well as a review of observational studies, suggest that 
antibiotic use could reduce infection risk after such an 
invasive procedure.
The guideline recommends against the indiscriminate 
application of minor procedures (eg, pubic hair shaving 
and frequent vaginal examinations during labour) 
or anti microbial use in conditions where there is no 
evidence of clinical beneﬁ ts to justify practice. This 
applies to routine vaginal antiseptic cleansing of women 
during vaginal birth, which has been widely proposed 
as a simple intervention with the potential to prevent 
maternal and neonatal infections.  However, evidence 
from randomised controlled trials comparing vaginal 
douching or irrigation with chlorhexidine versus sterile 
water showed no clinical beneﬁ ts of this intervention. 
Similar results came from a review of randomised 
controlled trials among women colonised with group 
B streptococcus (GBS), in whom the use of vaginal 
chlorhexidine also failed to show protective eﬀ ect 
against GBS-related neonatal infections. Hence, the 
current guideline does not recommend the routine 
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for preventing infectious morbidities in mothers and 
their neonates. In making these recommendations, 
the guideline panel emphasised the importance of 
promoting interventions that minimise interference 
with the natural process of labour and enhance women’s 
autonomy and dignity.
Clear recommendations are also made against the use 
of prophylactic antibiotics for all women with the aim 
of reducing infections during pregnancy or following an 
uncomplicated (or “uneventful”) vaginal birth, as well as 
for some obstetric procedures believed to increase risk 
of infection such as assisted vaginal birth (with forceps 
or vacuum) and episiotomy. These recommendations 
generally support the global eﬀ orts to reduce emerging 
antimicrobial resistance and are in line with the WHO 
global action plan on the containment of antimicrobial 
resistance.6
Despite the very low quality evidence to support 
comparative eﬀ ectiveness of one antibiotic over another 
to treat maternal infections, the current guideline 
conditionally recommends speciﬁ c classes of antibiotics 
for the management of chorioamnionitis (ampicillin 
and gentamicin) and post-partum endometritis 
(clindamycin and gentamicin), but the panel 
acknowledged that other simple, eﬀ ective, and locally 
available antibiotics could be used as an alternative. 
The guideline panel identiﬁ ed a set of principles 
of good clinical practice that are needed to optimise 
the eﬀ ects of the interventions recommended in the 
guideline. For instance, it highlights the need for health 
practitioners and managers to provide an enabling 
environment for infection prevention and control, 
changing their attitudes and practices and mobilising 
resources to ensure that adequate sanitation facilities 
are in place, hygiene and infection control measures are 
implemented, and antimicrobial agents are accessible. It 
also highlights the need to harness institutional eﬀ orts 
to identify puerperal infections promptly and provide 
the appropriate treatment. 
Key research priorities were identiﬁ ed, particularly 
related to conditions or procedures that are prevalent 
globally such as the use of prophylactic antibiotics 
for episiotomy, uncomplicated vaginal birth, or 
prolonged rupture of membranes at term. The eﬀ ects 
of antibiotics given before caesarean section on infant 
health also requires further investigation. To achieve 
the desired goal, WHO recommends that the guideline 
implementation and its impact should be monitored at 
the health service, regional, and country levels, on the 
basis of clearly deﬁ ned indicators that are associated 
with locally agreed targets.
*Mercedes Bonet, Olufemi T Oladapo, Dina N Khan, 
Matthews Mathai, A Metin Gülmezoglu
UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of 
Research, Development and Research Training in Human 
Reproduction, Department of Reproductive Health and Research 
(MB, OTO, DNK, AMG) and Department of Maternal, Newborn, 
Child and Adolescent Health (MM), WHO, 1211 Geneva 27, 
Switzerland
bonetm@who.int
WHO is grateful to all individuals and organisations that contributed to this 
guideline, including the members of the Guideline Development Group, and 
especially to James Neilson, for chairing the technical consultation. WHO 
acknowledges the special contribution of the Cochrane Pregnancy and Childbirth 
Group, University of Liverpool, UK, for coordinating the update of relevant 
Cochrane reviews, and the Department of Health Policy, National Research 
Institute for Child Health and Development, Tokyo, Japan, for its contribution to 
updating and reviewing the scientiﬁ c evidence used in the guideline. The US 
Agency for International Development provided ﬁ nancial support for this work. 
The views of the funding body have not inﬂ uenced the content of this guideline. 
We declare no competing interests.
©2015 World Health Organization; licensee Elsevier. This is an Open Access 
article published without any waiver of WHO’s privileges and immunities under 
international law, convention, or agreement. This article should not be 
reproduced for use in association with the promotion of commercial products, 
services or any legal entity. There should be no suggestion that WHO endorses 
any speciﬁ c organisation or products. The use of the WHO logo is not permitted. 
This notice should be preserved along with the article’s original URL.
1 WHO. World Health Report 2005: make every mother and child count. 
Geneva: World Health Organization, 2005. http://www.who.int/whr/2005/
whr2005_en.pdf (accessed Sept 21, 2015).
2 Dolea C, Stein C. Evidence and information for policy: global burden of 
maternal sepsis in the year 2000. Geneva: World Health Organization, 2003.
3 Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO 
systematic analysis. Lancet Glob Health 2014; 2: e323–33.
4 WHO. WHO recommendations for the prevention and treatment of 
maternal peripartum infections. Geneva: World Health Organization, 2015. 
http://www.who.int/reproductivehealth/publications/maternal_perinatal_
health/peripartum-infections-guidelines.
5 Morisaki N, Ganchimeg T, Ota E, et al. Maternal and institutional 
characteristics associated with the administration of prophylactic 
antibiotics for caesarean section: a secondary analysis of the World Health 
Organization Multicountry Survey on Maternal and Newborn Health. 
BJOG  2014; 121 (suppl 1): 66–75.
6 WHO. Antimicrobial resistance: global report on surveillance. Geneva: World 
Health Organization, 2014. http://apps.who.int/iris/bitstream/10665/ 
112642/1/9789241564748_eng.pdf (accessed Sept 21, 2015).
